Brief: NFL Biosciences/Themis Medicare: Partnership To Develop NFL-101, Drug Candidate For Smoking Cessation

Nfl Biosciences SAS

05/10/2022 17:55

Oct 5 (Reuters) - Nfl Biosciences SAS  ALNFL.PA :
    * ENTERED PARTNERSHIP TO DEVELOP NFL-101, COMPANY’S DRUG
CANDIDATE
FOR SMOKING CESSATION, FOR INDIAN MARKET WITH THEMIS MEDICARE
    * REG-NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE
DEVELOPMENT OF NFL-101 IN INDIA
    * COST OF PROCESS, FROM SUBMISSION TO COMPLETION OF STUDY,
WILL BE
CARRIED OUT BY THEMIS MEDICARE
    * THEMIS WILL PURCHASE FROM NFL BIOSCIENCES NFL-101 ACTIVE
PHARMACEUTICAL INGREDIENT (API), NFL WILL ALSO RECEIVE DOUBLE 
DIGIT ROYALTIES ON SALES
    * ONCE STUDY IS APPROVED, CLINICAL TRIAL WILL BE CONDUCTED
IN
INDIA, TARGETING 334 SMOKERS

Source text for Eikon:  ID:nGNE46CbVc 
Further company coverage:  ALNFL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))